Sai Parenteral’s Limited IPO is opening for subscription on March 24, 2026. The company operates in the pharmaceutical formulations and CDMO space and has shown steady growth in recent years.
With increasing investor interest in pharma IPOs, the key question is — Is Sai Parenteral IPO worth investing at current valuation? In this article, we will analyze Sai Parenteral IPO details, company background, financial performance, valuation, risk factors and provide our view on whether investors should subscribe or avoid.
About Sai Parenteral’s Limited
Sai Parenteral’s Limited was incorporated in 2001 and is engaged in pharmaceutical formulations and contract manufacturing (CDMO).
The company manufactures a wide range of products across multiple therapeutic segments such as cardiovascular, anti-diabetic, respiratory, antibiotics and dermatology.
It operates 5 manufacturing facilities in India, primarily in Hyderabad, with several international accreditations.
The company has recently expanded into export markets like Australia, Southeast Asia, Middle East and Africa, which could drive future growth.
Sai Parenteral IPO Issue Details
Sai Parenteral IPO is a book-built issue of around ₹409 Crores.
- Fresh Issue: ₹285 Crores
- Offer for Sale: ₹124 Crores
The IPO opens on March 24, 2026 and closes on March 27, 2026.
The price band is fixed at ₹372 to ₹392 per share.
Retail investors need to apply for a minimum of 38 shares, which requires an investment of ₹14,896 at upper price band.
The shares are proposed to be listed on NSE and BSE.
Company Financials (Restated)
Sai Parenteral has shown steady growth in revenue and profitability:
- Revenue increased from ₹97 Crores (FY23) to ₹164 Crores (FY25)
- Profit after tax increased from ₹4.38 Crores (FY23) to ₹14.43 Crores (FY25)
However, recent period (Sep 2025) indicates slight pressure on margins, which investors should watch closely.
The company has improved its net worth significantly and reduced borrowings, which is a positive sign.
Key Performance Indicators
- ROE (FY25): 16.82%
- ROCE (FY25): 28.92%
- EBITDA Margin: ~24%
- PAT Margin: ~9%
👉 While profitability ratios are decent, they are not exceptional to justify very high valuation.
Valuation Analysis – P/E Comparison with Peers
Sai Parenteral IPO is priced at a P/E of around 111x, which looks expensive.
Let us compare with peers:
- Sai Life Sciences – ~108x
- Senores Pharma – ~64x
- Gland Pharma – ~45x
- Innova Captab – ~32x
👉 Industry average P/E is around 62x
Valuation Verdict
- Sai Parenteral is priced much higher than industry average
- Even compared to highest peer, it is at a premium
- Growth exists, but valuation already discounts future potential
👉 This IPO appears OVERPRICED
Competitive Strengths
Sai Parenteral has several strengths:
- Diversified pharma product portfolio
- Growing CDMO business (high margin segment)
- Strong manufacturing capabilities with certifications
- Expansion into global markets
- Experienced management team
Risk Factors
Investors should also consider the following risks:
- High valuation compared to peers
- Recent margin pressure
- Highly competitive pharma industry
- Regulatory risks
- Offer for Sale portion (partial exit by investors)
Objects of the Issue
The company plans to use IPO proceeds for:
- Capacity expansion
- Setting up R&D center
- Debt repayment
- Working capital
- Overseas acquisition (Australia)
These are growth-oriented initiatives.
Sai Parenteral IPO – Should You Invest?
Positive Factors
- Strong pharma sector outlook
- Growth potential in CDMO and exports
- Improving financial performance
Concerns
- Expensive valuation (P/E ~111x)
- Margins showing pressure
- Return ratios not very strong
- Limited margin of safety
Myinvestmentideas View – Sh0uld you Subscribe or Avoid?
Sai Parenteral is a decent pharma company with good growth opportunities. However, the IPO is priced aggressively.
Investors should avoid chasing expensive IPOs and instead wait for better entry opportunities post listing.
- Sai Parenteral IPO Review – Price Band, Financials, P/E Comparison & Should You Invest? - March 22, 2026
- Amir Chand Jagdish Kumar IPO Review – Price Band, Financials, Lot Size and Should You Invest? - March 21, 2026
- Powerica IPO Review 2026 – Price Band, Financials, P/E Comparison & Should You Invest? - March 21, 2026